Business Context and Reporting Period
Company: SBC Medical Group Holdings Inc (SBC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: SBC is a holding company providing comprehensive management services to aesthetic clinics, primarily in Japan, through franchise and service agreements with Medical Corporations (MCs). The company also operates clinics in Singapore and Vietnam and pursues U.S. market entry via strategic investments. The company operates as a single reporting segment.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $173.61 million | $205.42 million |
| Net Income | $51.05 million | $46.69 million |
| Net Income Attributable to SBC | $50.99 million | $46.61 million |
| Gross Profit Margin | 73.32% | 75.97% |
| Operating Income | $67.49 million | $70.30 million |
| Operating Cash Flow | $24.67 million | $20.58 million |
| Cash and Cash Equivalents (Year End) | $163.77 million | $125.04 million |
| Total Debt (Bank Borrowings) | $42.83 million | $6.60 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 15.5% to $173.61 million. This was primarily driven by a 24.7% drop in Franchising revenue and a 44.2% drop in Management Services revenue. These declines resulted from a revised fee structure effective April 2025 (shifting from flat fees to performance-based tiers) and the discontinuation of certain staff support services.
- Profitability Increase: Despite lower revenue, Net Income increased 9.3% to $51.05 million. This was largely due to a significant reduction in Operating Expenses (down 30.3%), driven by the absence of a $15.1 million impairment loss on intangible assets and a $13.0 million stock-based compensation expense recorded in 2024.
- Other Income Surge: Other income increased 362.5% to $14.58 million, primarily due to an $8.75 million gain on the redemption of life insurance policies and a $2.0 million foreign currency exchange gain.
- Debt Expansion: Total bank borrowings increased significantly from $6.60 million to $42.83 million to fund acquisitions and working capital.
Guidance, Outlook, and Risks
Recent Developments and Strategy
- Acquisitions: Completed acquisition of Waqoo, Inc. (regenerative medicine) in December 2025 (consolidated with a 3-month lag). Acquired MB career lounge (management support) in July 2025. Acquired Aesthetic Healthcare Holdings (Singapore) in November 2024.
- Strategic Investment: Acquired an 18.2% minority interest in OT Midco (OrangeTwist, U.S. medical aesthetics) for $20 million in December 2025, with a commitment for an additional $5 million in 2026.
- Share Repurchase: Authorized a new $20 million share repurchase program in December 2025, effective through December 31, 2026.
- Fee Structure: Implemented a tiered, performance-based fee structure for franchisees in April 2025 to support new clinic growth and align fees with operational scale.
Material Risks and Contingencies
- Internal Control Weaknesses: The company disclosed that disclosure controls and procedures were not effective as of December 31, 2025. Material weaknesses persist regarding the oversight and approval of related party transactions and executive compensation. Specifically, compensation paid to the CEO's mother and a bonus to the CFO were not timely identified or approved by the appropriate committees.
- Related Party Concentration: The company relies heavily on a limited number of Medical Corporations (MCs) for revenue, all of which are related parties controlled by relatives of the CEO. The CEO beneficially owns approximately 85.2% of the voting power.
- Regulatory and Legal: A stockholder class action complaint was filed in February 2026 alleging violations regarding director removal provisions in the company charter. The company faces risks related to data privacy (APPI in Japan), medical regulations, and potential delisting from Nasdaq if financial thresholds are not met.
Investor Verification Checklist
- Remediation of Internal Controls: Verify the specific steps taken to remediate the material weaknesses in related party transaction oversight and executive compensation approval, and the timeline for achieving effectiveness.
- Related Party Transactions: Review the nature and pricing of transactions with the Medical Corporations (MCs) and entities controlled by the CEO to ensure arm's-length terms.
- Revenue Sustainability: Assess the long-term impact of the April 2025 fee structure revision on future revenue growth and whether the decline in management service fees is a one-time adjustment or a structural shift.
- Acquisition Integration: Monitor the financial performance and integration of Waqoo, Inc. and OrangeTwist, noting the reporting lag for Waqoo results.
- Debt Servicing: Evaluate the company's ability to service the increased debt load ($42.8 million) given the decline in core operating revenue.